Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS

Area of Science:

• Immunology
• Pulmonology
• Biomarker Discovery

Background:

• Decreased serum immunoglobulin A (IgA) levels are linked to infection risk in some populations.
• The association between subnormal serum IgA and exacerbation risk in Chronic Obstructive Pulmonary Disease (COPD) has not been studied.
• This study investigated the hypothesis that lower serum IgA levels correlate with increased exacerbation risk in COPD.

Purpose of the Study:

• To test the hypothesis that subnormal serum IgA levels are associated with exacerbation risk in COPD.
• To explore the relationship between serum IgA levels and the incidence of exacerbations in COPD patients.
• To determine if a dose-response relationship exists between lower serum IgA and exacerbation frequency.

Main Methods:

• Analysis of data from 1,049 COPD participants in the SPIROMICS cohort.
• Baseline serum IgA levels were measured using the Myriad RBM biomarker discovery platform.
• Prospective collection of exacerbation data and adjusted regression analyses were performed.

Main Results:

• A total of 2.4% of participants had serum IgA levels ≤70 mg/dL.
• Serum IgA levels ≤70 mg/dL were associated with higher exacerbation incidence rates (IRR 1.71) and increased risk for severe exacerbations (OR 2.99).
• Among participants in the lowest IgA decile, each 10 mg/dL decrease in IgA was linked to more exacerbations (β 0.24).

Conclusions:

• Subnormal serum IgA levels are associated with an increased risk of acute exacerbations in COPD.
• These findings suggest that mildly impaired IgA levels may contribute to COPD morbidity.
• A dose-response relationship was observed, reinforcing the link between serum IgA levels and exacerbation risk in COPD.